Press Releases

Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022

Biopharma PEG Offers GMP & Non-GMP Grade PEG Derivatives Manufacture Services

Huateng Pharma Develops Sitagliptin & Linagliptin Anti-diabetic Intermediates

Emmes Acquires Clinical Edge

In latest news story from Emmes (CRO) announcing the acquisition of Clinical Edge, which trains and certifies visual function examiners at investigator sites conducting Phase I to IV ophthalmic clinical trials. OptymEdge - The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services.

Monon Bioventures receives nearly $400,00 funding to develop Purdue-discovered glioblostoma treatment

Monon Bioventures receives funding to develop glioblostoma treatment

Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts

Quanticate partners with Cancer Research UK to launch DETERMINE Study

Heart pacing company Ceryx Medical partners with Osypka Medical

Ceryx Medical Limited has announced a partnership with Berlin-based Osypka Medical to develop a heart pacing device that will change the way patients with heart failure and other cardiac conditions are treated.

Creative Biostructure Uncovers Insights for Pathology Research with Advanced iEM Platform

Lifeasible Released Rare Plant Tissue Culture Service to for Research Use

Matexcel Provides a Wide Range of Metal Oxide Products for Research Use

Bora Pharmaceuticals partners with TaiRx, Inc. to manufacture breakthrough anticancer drug

BioIVT Acquires Fidelis Research

This transaction increases BioIVT's global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.

Abzena strengthens R&D capabilities to support rapid antibody discovery

For further information, images, and interview opportunities, please contact Kristy Harmer at ramarketing: kristy.harmer@ramarketingpr.com | +44 (0)191 222 1242 | ramarketingpr.com | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing About Abzena Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com

Zebrafish Disease Models: Accelerating Human Disease Studies and Biomedical Research

Microbiosci Offers Real-time PCR Kits to Support Research Applications in Viral Detection

CRISPR/Cas9 Platform Provides Accurate Gene Knockout Mouse Models for Immunology Research and Drug Discovery

Creative Bioarray Provides Cell Patterning Customization and Detection Services for Drug Screening

DDA Platform Offers A Wide Range of in Vitro and in Vivo Assays to Cover Early Stage Drug Discovery

Creative Bioarray Designs Comprehensive Tools and Protocols to Construct Animal Disease Models